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Abstract
Introduction: Intensive insulin treatment (IIT) has been shown to improve outcomes post-burn in severely burnt
patients. However, it increases the incidence of hypoglycemia and is associated with risks and complications. We
hypothesized that exenatide would decrease plasma glucose levels post-burn to levels similar to those achieved
with IIT, and reduce the amount of exogenous insulin administered.
Methods: This open-label study included 24 severely burned pediatric patients. Six were randomized to receive
exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were
administered to maintain glucose levels between 80 and 140 mg/dl. We determined 6 AM, daily average,
maximum and minimum glucose levels. Variability was determined using mean amplitude of glucose excursions
(MAGE) and percentage of coefficient of variability. The amount of administered insulin was compared in both
groups.
Results: Glucose values and variability were similar in both groups: Daily average was 130 ± 28 mg/dl in the
intervention group and 138 ± 25 mg/dl in the control group (P = 0.31), MAGE 41 ± 6 vs. 45 ± 12 (respectively).
However, administered insulin was significantly lower in the exenatide group than in the IIT group: 22 ± 14 IU
patients/day in the intervention group and 76 ± 11 IU patients/day in the control group (P = 0.01). The incidence
rate of hypoglycemia was similar in both groups (0.38 events/patient-month).
Conclusions: Patients receiving exenatide received significantly lower amounts of exogenous insulin to control
plasma glucose levels. Exenatide was well tolerated and potentially represents a novel agent to attenuate
hyperglycemia in the critical care setting.
Trial registration: NCT00673309.
Introduction
Hyperglycemia is a common finding in critically ill
patients that has been associated with increased morbid-
ity and mortality. In burns, it has also been shown that
hyperglycemia is deleterious. Gore et al. [1] found that
hyperglycemia was associated with an increased rate of
muscle protein catabolism [2] and increased morbidity
and mortality in this population. In addition, Hemmila
et al. [3] found that IIT was associated with a lower
incidence of pneumonia, ventilator-associated pneumo-
nia and urinary tract infections; and Pham et al.[ 4 ]
reported similar findings and a positive association of
IIT with survival rates following IIT treatment in pedia-
tric burned patients. Our group has recently shown that
IIT in severely burned pediatric patients was associated
with improved post-burn morbidity, such as infection,
sepsis, and organ function [5].
However, the Normoglycemia in Intensive Care Eva-
luation and Survival Using Glucose Algorithm Regula-
tion (NICE-SUGAR) found no benefit and an increased
incidence of hypoglycemia with IIT in adult critical care
[6,7]. However, detailed analysis of the NICE-SUGAR
study suggests a better outcome within the trauma sub-
population with intensive insulin treatment [6].
Since current evidence supports the use of IIT in
trauma patients, the study of novel therapies to decrease
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risk of hypoglycemia is warranted [8]. Incretin-based
therapies are currently among the newest classes of
available glucose-lowering agents [9]. The incretin effect
consists of higher insulin production after an oral inges-
tion of glucose than after an intra-venous load one [10].
The incretins that have been identified are glucose-
dependent insulinotropic peptide (GIP) and glucagon-
like peptide-1 (GLP-1). Exogenous GLP-1 has been
shown to reduce glucose concentration when adminis-
tered to hospitalized patients [11,12]. Activation of the
incretin receptors on b-cells increases insulin release in
response to glucose [13] and may have additional bene-
ficial effects, as it has been suggested that these drugs
promote enhanced glucose disposal in peripheral tissues
and protect against ischemia/reperfusion injury [14].
Exenatide is a synthetic peptide originally identified in
the lizard Heloderma suspectum [15] that possesses
incretin-mimetic actions including suppression of gluca-
gon secretion and delay of gastric emptying [16]. It has
been shown to bind and activate the human glucagon-
like peptide-1 (GLP-1) receptor in vitro [17]. We
hypothesized that exenatide would decrease the amount
of exogenous insulin administered to the patients and
the incidence of hypoglycemia in the acute setting of
severely burned pediatric patients.
Materials and methods
Patients
Twenty-four severely burned pediatric patients were
recruited for the study. This study was approved by the
Institutional Review Board of The University of Texas
Medical Branch. The patient, parent or legal guardian
signed an informed consent for this study.
Medical care
Medical care was determined by faculty surgeons, fel-
lows, and residents according to clinical protocols that
have been previously describ e d[ 1 8 ] .B r i e f l y ,p a t i e n t s
were fed with Vivonex® T.E.N. (total enteral nutrition).
(Novartis, Minneapolis, MN, USA; 82% carbohydrate,
15% protein, 3% fat, glutamine 4.9 g/L and L-Arginine
2.9 g/L) at 1.4 times their measured resting energy
expenditure (REE) [4] and initiated within 48 h after a
burn injury. The nutritional route of choice in our
patient population was enteral nutrition via a duodenal
(Dobhof) tube. The patients received nutritional supple-
ments including multivitamin (Enfamil Poly-Vi-Sol ®,
Mead Johnson & Company, LLC, Evansville, IN USA)
29.5 ml (1 fl oz) per os (PO) daily; folic acid 1 mg PO
three days a week; zinc sulfate PO 55 mg for patients
under 2 years old, 110 mg for patients 3 to 11 years old
and 220 mg for patients older than 12 years old; and
vitamin C 250 mg PO for patients under 12 years old
and 500 mg for patients 12 years old and older. Burn
patients were excluded from participation if they were
diagnosed with diabetes mellitus before the burn injury.
We used oral glucose tolerance tests, medical history
and determinations of glycosylated hemoglobin
(HbA1C) to detect diabetic patients. Potential side
effects of GLP-1, such as gastrointestinal symptoms (for
example, nausea, pyrosis), injection site reactions and
hypersensitivity symptoms, were prospectively evaluated
and documented.
Indirect calorimetry
As part of our routine clinical practice, all patients
underwent REE measurements within one week follow-
ing hospital admission and weekly thereafter during
their acute hospitalization. All measurements of REE
were performed between midnight and 5 a.m. while the
patients were asleep and receiving continuous feeding.
REE was measured using a Sensor-Medics Vmax 29
metabolic cart (Yorba Linda, CA, USA) calibrated
according to the manufacturer instructions as previously
published [19]. The REE was calculated from the oxygen
consumption and carbon dioxide production by equa-
tions described by Weir et al. [20]. Measured values
were compared to predicted norms based upon the Har-
ris-Benedict equation [21] and to body mass index
(BMI). For statistical comparison, energy expenditure
was expressed as the percentage of the basal metabolic
rate predicted by the Harris-Benedict equation.
T h ep a t i e n t si nt h i ss t u d ywere mechanically venti-
lated only for operative procedures and there was no
difference in mechanical ventilation between both
groups.
Treatment
Participants were randomly assigned (block randomiza-
tion 1:3) during their acute hospitalization (until 95%
healed) to exenatide treatment and insulin as an adjunct
if needed, or only intensive insulin. Patients assigned to
exenatide received exenatide (Amylin Pharmaceuticals,
Inc., San Diego, CA, USA) subcutaneous (SQ) and insu-
lin, if needed, to maintain plasma glucose levels between
80 and 140 mg/dl.
Exenatide was adjusted to plasma glucose levels. It was
initiated with 5 μg of exenatide q 12 h increasing the
dose to 10 μg up to q 4 h if glucose levels were above
target. If the glucose was still above target, we then
added insulin therapy as described below.
The intensive insulin treatment (IIT) patients were
treated with intensive insulin to maintain plasma glu-
cose levels between 80 and 140 mg/dl.
Regular insulin was administered in a sliding scale to
titrate to 80 to140 mg/dl. Infusion started at a rate of
0.1 U/kg/h, with increments ranging from 0.1 U/kg/h
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kg/h when glucose was greater than 260 mg/dl.
Laboratory
Blood samples for glucose determination were obtained
during the acute hospitalization and analyzed in the
laboratory of the hospital. In all the patients, glucose
levels were measured in a panel with liver enzymes and
electrolytes. Insulin levels were determined by ELISA.
Initially, and if any change in insulin infusion or feeding
occurred or if glucose levels were not in the desired
range, glucose was checked every 15 minutes until stable
(defined as three consecutive measurements with glu-
cose on range). Once stable, determinations were
reduced every two hours. Routine glucose determina-
tions were performed on a daily basis at 06:00 h.
In all the patients with at least three glucose determi-
nations, the daily average, maximum and minimum glu-
cose levels were determined. For those patients with one
to two glucose values per day, only 6 AM glucose was
used for calculations of daily average. A hypoglycemic
event was defined as plasma glucose level < 60 mg/dl
preceded by at least two normal values.
Mean amplitude of glucose excursion (MAGE)
and percentage of coefficient of variance (% CV) were
used to assess variability of glucose values. MAGE
assesses the average amplitude of upstrokes and down-
strokes with magnitude greater than one standard
deviation [22]. The %CV is defined as: %CV = 100*SD/
mean [23].
Statistical analysis
We used the Mann-Whitney U test and Chi square ana-
lysis. Data are expressed as means ± SD or SEM, where
appropriate (SigmaStat v3.5.1.2 Heame Scientific Soft-
ware, Chicago, IL, USA). Significance was accepted at
P < 0.05.
Results
Six patients were randomized to the treatment group
and 18 patients to the IIT group (Figure 1). Demo-
graphics showed no significant difference between both
groups (Table 1). Glucose values were similar in both
groups (Table 2). The number of glucose determinations
was similar between both groups: 143 ± 38 for the exe-
natide group and 139 ± 59 for the IIT group (P = 0.79).
Longitudinal analysis of all the glucose values (6 AM,
daily, maximum and minimum glucose levels) along the
acute stay showed similar values in both groups (Figure
2). The incidence rate of days with less than three glu-
cose determinations per acute stay was 15.5 days/30
days for the IIT group and 14.5 days/30 days in the exe-
natide group (P > 0.05).
Patients in the IIT group received significantly more
insulin to maintain similar glucose levels when com-
pared to the exenatide patients (P =0 . 0 1 ) ,w h i l es e r u m
insulin levels (endogenous and exogenous) were not
significantly different between both groups (P > 0.05)
( F i g u r e3 ) .T h r e ep a t i e n t si nt h ee x e n a t i d eg r o u pd i d
not receive exogenous insulin, while all the patients in
the IIT group received insulin.
The MAGE was not statistically different between
both groups (P = 0.61) (Figure 4). Similarly, % CV was
similar in both groups (Figure 5).
The incidence rate of hypoglycemia was similar in
both groups (0.38 events/patient-month). There were 17
events of moderate hypoglycemia (40 to 59 mg/dl) and
1 of severe hypoglycemia (< 40 mg/dl) in the IIT group
and 6 events of moderate hypoglycemia and none of
severe hypoglycemia in the exenatide group.
The REE [4] was not significantly different between
the groups (Figure 6). The total amount of calories
administered to the patients is shown in Figure 7. It was
not different between groups.
Exenatide was well tolerated by all the patients and no
adverse reaction associated with the administration of
exenatide was documented. There was no mortality in
any of the groups.
Discussion
Incretin-based drugs are a family of substances that lower
glucose levels by enhancing glucose-dependent secretion
of insulin, a condition known as the incretin effect [24].
Incretin-based drugs require a hyperglycemic state for
their effects [25], thus, hypoglycemia is uncommon even
with high-doses of the drugs [26]. This and many other
described effects of GLP-1 analogues, such as increased
endogenous insulin secretion and peripheral glucose
uptake and protection against ischemia/reperfusion,
made these drugs particularly suitable for burn patients.
O t h e rd r u g sm a yd e c r e a s eg l u c o s el e v e l sw i t hal o wr i s k
of hypoglycemia or may increase peripheral glucose
uptake, but in theory with GLP-1 analogues we would
achieve these effects with only one drug.
Among the incretin-based drugs, we decided to
administer exenatide because it is known that it binds
with equal affinity to the GLP-1 receptor and produces
similar glucose-lowering actions to GLP-1 [27]. Addi-
tionally, exenatide is known to increase insulin-depen-
dent glucose uptake in muscle and fat while GLP-1 does
not have such action [28]. Furthermore, its longer half-
life allows for subcutaneous administration q- 12 h facil-
itating the management of severely burned patients in
the ICU. According to its described effects, we expected
that patients receiving exenatide treatment would
receive less exogenous insulin. Since hyperglycemia was
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groups to achieve normal levels, we did not expect sig-
nificantly different glucose levels between patients, as
observed.
Variability of glucose has been associated with
increased mortality and has been considered one of the
most important goals of glucose management in ICU
[29]. We, therefore, included analysis of MAGE.
Although mean MAGE was lower in the patients receiv-
ing exenatide, with the actual sample size it is not possi-
ble to make any conclusion on this regard. We found
no difference in the incidence of hypoglycemic events in
both groups, probably as a result of the insulin adminis-
tration with a target glucose level of 80 to 140 mg/dl in
all patients. By modifying the target glucose level, we
hypothesize that the incidence of hypoglycemia would
decrease in these patients. Further studies are necessary
Figure 1 CONSORT diagram. Eligibility and enrollment of patients.
Table 1 Demographics
Demographics IIT Exenatide P value
Age (years) 12 ± 4 12 ± 5 NS
Gender (M:F) (3.5:1) (5:1) NS
Weight (kg) 41 ± 19 49 ± 23 NS
Height (cm) 145 ± 28 144 ± 26 NS
TBSA (%) 61 ± 16 56 ± 13 NS
3
rd (%) 51 ± 25 46 ± 19 NS
Type of burn
Flame 67% 83% NS
Scald 6% 0 NS
Electrical 27% 17% NS
Demographics of the patients per group. Values are represented as mean ±
standard deviation. IIT, intensive insulin treatment; TBSA, total body surface
area; 3
rd, percentage of total body surface area with 3
rd-degree burn; NS, not
significant (P -value > 0.05).
Table 2 Glucose values
Glucose
value
Intensive insulin
treatment
Exenatide P-
value
Six AM 123 ± 35 mg/dl 132 ± 27 mg/
dl
0.39
Maximum 167 ± 45 mg/dl 171 ± 40 mg/
dl
1.00
Minimum 98 ± 29 mg/dl 107 ± 26 mg/
dl
0.09
Daily average 130 ± 28 mg/dl 138 ± 25 mg/
dl
0.31
Average glucose values per group. Values are represented as mean ±
standard deviation. NS, Not significant (P- value > 0.05).
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morbidity and mortality in the burn population.
This study was designed as an open-label pilot study
and was one of the multiple trials we conduct at our
institute. At our institute, we have several clinical trials
to study the effect of anti-catabolic, anabolic, and glu-
cose modulation agents. The primary aim of the present
study was to assess efficacy and feasibility (that is, effects
on insulin and glucose metabolism) in a limited patient
population. Based on previous efficacy studies at our
institute, we hypothesized that we would need about six
patients in the intervention group. In order to decrease
variability and decrease the low sample error, we rando-
mized three times as many patients (18 patients) to the
control group. We are clearly underpowered to draw
any conclusions on the effect of GLP-1 on morbidity or
mortality. However, we demonstrated in the present
open label trial that GLP-1 appears to be a safe adjunct
therapy to achieve glucose in a pediatric burn
population.
Exenatide was originally described as a therapy for adult
diabetic patients, and although its use in pediatric patients
has been suggested [30,31], the available literature about
its use and safety in these patients is scarce at best. It has
been described that exenatide may cause some adverse
effects that can be severe (for example, pancreatitis) [32].
However, we did not observe complications or any unde-
sirable effect associated with exenatide administration in
the studied patients (for example, gastrointestinal symp-
toms, injection site reactions and hypersensitivity).
This study has limitations due to the small number of
patients and the fact that the treatment was not blinded
for safety reasons. A larger sample size would be neces-
sary to assess other aspects, such as true complication
rate, variability of glucose and the effect of exenatide on
hypoglycemia and REE. The percent predicted REE was
Figure 2 Glucose values. Longitudinal analysis of the different glucose values along the 30 days of study. If less than three glucose values were
obtained, maximum and minimum values were not calculated (see text for details). (a) Daily average. (b) Maximum. (c) Minimum. (d) Six AM
glucose levels. IIT: Intensive insulin treatment. All values are represented as mean ± SEM.
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admission in the exenatide patients, although not statis-
tically significant. The absorption of exenatide after sub-
cutaneous administration might be inconsistent in
edematous patients. It has been shown that oral gluta-
mine increases circulating GLP-1 [33] potentially stimu-
lating endogenous GLP-1 secretion in the IIT group.
This might have affected the glucose metabolism in the
IIT group. Plasma concentration of exenatide and GLP-
1 should be included in future studies. It would have
also been interesting to determine C-peptide in plasma
to assess endogenous insulin production and glucagon
concentrations and we recommend doing so for future
studies. However, this study was the first attempt to
find alternate glucose lowering agents in the setting of
burn critical care. We believe that the utility of alterna-
tive drugs, (for example, peroxisome proliferator-acti-
vated receptors (PPAR) agonists), needs to be assessed
since many of these agents are less expensive and as
equally safe as GLP-1. Therefore, a study assessing the
utility of these drugs in the burn population is war-
ranted. In this trial, we found that exenatide was Figure 3 Exogenous insulin administered and insulin plasma
levels. (a) Insulin administered per patient per day. (b) Average of
administered insulin per patient per acute hospital stay. (c) Mean
plasma insulin levels. All values account for first 30 days of hospital
stay. Values are represented as mean ± SEM.
Figure 4 MAGE. Mean amplitude of glucose excursion. Expressed
as mean ± SEM.
Figure 5 Percentage of coefficient of variance (% CV).
Figure 6 Resting energy expenditure (REE). REE expressed as
percentage of predicted. All values are represented as mean ± SEM.
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pediatric population.
Conclusions
Administration of exenatide to severely burned pediatric
patients reduced the amount of administered exogenous
insulin and was well tolerated during their acute setting.
The GLP-1 analogue tested in this trial appears to be
safe and reliably modulates glucose in these patients.
Key messages
￿ The administration of exenatide resulted in a
reduced amount of administered exogenous insulin
in severely burn pediatric patients.
￿ Exenatide appears to be a safe and reliable glucose
modulator in these patients.
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